课题基金 / 基金详情

CLINICAL, MORPHOLOGIC AND MOLECULAR STUDIES

CLINICAL, MORPHOLOGIC AND MOLECULAR STUDIES
临床、形态学和分子研究
批准号:
6594612
负责人:
DAVID L RIMOIN
金额:
$17.7万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-05-28 至 2006-11-30

项目摘要

项目成果

DAVID L RIMOIN的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Description (provided by applicant): The skeletal dysplasias are a heterogeneous group of over 200 disorders. This project seeks to define the clinical and genetic and pathologic features of these disorders, develop animal models to better understand their pathogenesis, define the molecular defect in three disorders by linkage analysis and perform clinical molecular correlative studies with each of the other projects and other collaborators. During the period of support, we will: 1) definitively classify cases submitted to the International Skeletal Dysplasia Registry (Core A), improve the characterization of previously described skeletal dysplasias, and define novel disorders; 2) improve the methods used for prenatal diagnosis of the skeletal dysplasias; 3) correlate the clinical, radiographic, and morphological features of different skeletal dysplasias with their specific biochemical and molecular defects; 4) in collaboration with subprojects 5, 2, 8, and other workers analyze animal chondrodysplasias for identification of human homologues, validation of experimental models, and insight into the pathophysiology; and 5) localize the disease gene locus using linkage analysis and identify the genetic defect for three skeletal dysplasias where the basic defect is not known, specifically Desbuquois syndrome, autosomal dominant brachyolmia, and linked faciocardiomusculoskeletal syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
THE INTERNATIONAL SKELETAL DYSPLASIA REGISTRY
  • 批准号:
    8125466
  • 项目类别:
  • 资助金额:
    $20.91万
  • 财政年份:
    2010
  • 负责人:
    DAVID L RIMOIN
  • 依托单位:
The Skeletal Dysplasias
  • 批准号:
    7931042
  • 项目类别:
  • 资助金额:
    $5.06万
  • 财政年份:
    2009
  • 负责人:
    DAVID L RIMOIN
  • 依托单位:
CLINICAL TRIAL: TRIAL OF BETA BLOCKER THERAPY (ATENOLOL) VS ANGIOTENSIN II RECE
CLINICAL TRIAL: MUSCULOSKELETAL PHENOTYPE OF MARFAN PATIENTS